SEGMENTED INFORMATION (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
SEGMENTED INFORMATION
Net Income (Loss) Available to Common Stockholders, Basic	$ (616,172)	$ 199,104	$ (1,239,499)	$ 95,347
REVENUE	2,260,253	1,974,564	4,397,328	4,356,415
COST OF REVENUE (Including $2,307 and $28,766 of cost of revenue from related parties for the three month period ended June 30, 2025 and 2024, respectively, and $2,307 and $105,980 of cost of revenue from related parties for the six month period ended June 30, 2025 and 2024, respectively)	(1,892,231)	(1,685,844)	(3,685,813)	(3,702,664)
GROSS PROFIT	368,022	288,720	711,515	653,751
Dividend income	8,626	11,881	17,560	20,827
Interest income	29,768	49,739	53,336	78,722
Fair value gain on investments in equity securities	23,742	88,532	28,256	173,317
Gain on disposal of investments in equity securities		8,117		14,298
Reversal of expected credit losses	69,759	552,663	94,912	584,415
Others	77,566	19,173	106,817	60,373
OTHER INCOME	209,461	730,105	300,881	931,952
Sales and marketing	(608,427)	(136,494)	(1,149,122)	(290,365)
Research and development	(12,557)	(8,198)	(24,696)	(19,673)
General and administrative	(516,790)	(558,829)	(908,666)	(874,623)
Fair value loss on investments in equity securities	(51,002)	(56,136)	(119,499)	(100,433)
Provision for expected credit losses			(40,124)	(120,469)
TOTAL OPERATING EXPENSES	(1,188,776)	(759,657)	(2,242,107)	(1,405,563)
LOSS FROM OPERATIONS	(611,293)	259,168	(1,229,711)	180,140
FINANCE COSTS	(4,879)	(4,480)	(9,788)	(9,141)
LOSS BEFORE TAX	(616,172)	254,688	(1,239,499)	170,999
Tax expense	0	(55,584)	0	(75,652)
Provision For Genomic Screening Services [Member]
SEGMENTED INFORMATION
Net Income (Loss) Available to Common Stockholders, Basic	(164,108)	(66,502)	(237,700)	(109,700)
REVENUE	3,466	5,496	6,534	8,661
COST OF REVENUE (Including $2,307 and $28,766 of cost of revenue from related parties for the three month period ended June 30, 2025 and 2024, respectively, and $2,307 and $105,980 of cost of revenue from related parties for the six month period ended June 30, 2025 and 2024, respectively)	(2,725)	(2,353)	(4,131)	(4,605)
GROSS PROFIT	741	3,143	2,403	4,056
Dividend income	0	0	0	0
Interest income	25,092	37,154	45,094	60,937
Fair value gain on investments in equity securities	0	0	0	0
Gain on disposal of investments in equity securities		0		0
Reversal of expected credit losses	0	0	0	0
Others	3,477	210	7,370	15,121
OTHER INCOME	28,569	37,364	52,464	76,058
Sales and marketing	(28,424)	(23,011)	(56,064)	(54,116)
Research and development	(12,557)	(8,198)	(24,696)	(19,673)
General and administrative	(149,164)	(73,154)	(205,170)	(111,429)
Fair value loss on investments in equity securities	0	0	0	0
Provision for expected credit losses		(104,363)	0	0
TOTAL OPERATING EXPENSES	(190,145)		(285,930)	(185,218)
LOSS FROM OPERATIONS	(160,835)	(63,856)	(231,063)	(105,104)
FINANCE COSTS	(3,273)	(2,646)	(6,637)	(4,596)
LOSS BEFORE TAX	(164,108)	(66,502)	(237,700)	(109,700)
Tax expense		0		0
Investment Holding [Member]
SEGMENTED INFORMATION
Net Income (Loss) Available to Common Stockholders, Basic	(226,504)	(374,248)	(441,349)	(523,694)
REVENUE	0	0	0	0
COST OF REVENUE (Including $2,307 and $28,766 of cost of revenue from related parties for the three month period ended June 30, 2025 and 2024, respectively, and $2,307 and $105,980 of cost of revenue from related parties for the six month period ended June 30, 2025 and 2024, respectively)	0	0	0	0
GROSS PROFIT	0	0	0	0
Dividend income	0	0	0	0
Interest income	0	0	0	0
Fair value gain on investments in equity securities	0	0	0	0
Gain on disposal of investments in equity securities		0		0
Reversal of expected credit losses	0	0	0	0
Others	0	0	0	0
OTHER INCOME	0	0	0	0
Sales and marketing	(20,462)	(10,226)	(24,527)	(12,550)
Research and development	0	0	0	0
General and administrative	(206,035)	(363,934)	(416,772)	(511,032)
Fair value loss on investments in equity securities	0	0	0	0
Provision for expected credit losses			0	0
TOTAL OPERATING EXPENSES	(226,497)	(374,160)	(441,299)	(523,582)
LOSS FROM OPERATIONS	(226,497)	(374,160)	(441,299)	(523,582)
FINANCE COSTS	(7)	(88)	(50)	(112)
LOSS BEFORE TAX	(226,504)	(374,248)	(441,349)	(523,694)
Tax expense		0		0
Trading Of Industrial Chemicals [Member]
SEGMENTED INFORMATION
Net Income (Loss) Available to Common Stockholders, Basic	(225,560)	639,854	(560,450)	728,741
REVENUE	2,256,787	1,969,068	4,390,794	4,347,754
COST OF REVENUE (Including $2,307 and $28,766 of cost of revenue from related parties for the three month period ended June 30, 2025 and 2024, respectively, and $2,307 and $105,980 of cost of revenue from related parties for the six month period ended June 30, 2025 and 2024, respectively)	(1,889,506)	(1,683,491)	(3,681,682)	(3,698,059)
GROSS PROFIT	367,281	285,577	709,112	649,695
Dividend income	8,626	11,881	17,560	20,827
Interest income	4,676	12,585	8,242	17,785
Fair value gain on investments in equity securities	23,742	88,532	28,256	173,317
Gain on disposal of investments in equity securities		8,117		14,298
Reversal of expected credit losses	69,759	552,663	94,912	584,415
Others	74,089	18,963	99,447	45,252
OTHER INCOME	180,892	692,741	248,417	855,894
Sales and marketing	(559,541)	(103,257)	(1,068,531)	(223,699)
Research and development	0	0	0	0
General and administrative	(161,591)	(121,741)	(286,724)	(252,162)
Fair value loss on investments in equity securities	(51,002)	(56,136)	(119,499)	(100,433)
Provision for expected credit losses			(40,124)	(120,469)
TOTAL OPERATING EXPENSES	(772,134)	(281,134)	(1,514,878)	(696,763)
LOSS FROM OPERATIONS	(223,961)	697,184	(557,349)	808,826
FINANCE COSTS	(1,599)	(1,746)	(3,101)	(4,433)
LOSS BEFORE TAX	$ (225,560)	695,438	$ (560,450)	804,393
Tax expense		$ (55,584)		$ 75,652